What Klava Innovation does

Klava Innovation, founded in 2021 and headquartered in Boulogne-Billancourt, France, is a privately held deeptech/medtech laboratory that develops digital therapeutics for addictive disorders. Its flagship product, Quitoxil®, is a CE-marked Class I medical device smartphone application that delivers cognitive-behavioral therapy (CBT) for smoking cessation, supported by self-assessments, progress tracking, peer support from certified former smokers, and machine-learning-based personalization intended to detect relapse risk early.

The company operates a hybrid distribution model. Patients can download the app directly from iOS and Android stores, but full therapeutic access is activated by a unique code generated when a healthcare professional issues a prescription through Klava's integration with AppThera, a CPS/e-CPS-enabled e-prescription platform. Medical delegates conduct field sales to pulmonologists, tabacologues, cardiologists, nurses, and midwives, and Quitoxil became the first French digital therapeutic distributed through pharmacies in September 2024. Reimbursement is partial-to-full through French mutuelles (€50–€300 per year), and Klava is targeting PECAN digital medical-device reimbursement in 2025. Revenue streams include direct app subscription sales, prescription-driven activation, and an emerging enterprise/B2B licensing motion targeting insurance carriers and corporate-wellness programs.

Klava's clinical credibility is anchored by a partnership with the addiction department of AP-HP Paul Brousse Hospital, described as the leading European addiction research center, and a scientific board chaired by a senior psychiatrist. The platform is hosted on HDS-certified Google Cloud infrastructure and is GDPR-compliant. With approximately 10–12 employees, a €1 million funding round in January 2024, and a 987-patient real-world study reporting 51% tobacco reduction and 81% 30-day engagement, Klava is positioned as a first-mover French digital therapeutic for addiction care, with stated ambitions to expand into alcohol, opioid, and sugar addictions and to scale across Europe.

Name

Klava Innovation

Legal name

KLAVA INNOVATION

Website

https://klava-innovation.com

Company type

Private

Founded year

2021

Operating status

Operating

Headcount range

1–10 employees

Ownership category

akta.pro rank

Product category

Digital Therapeutics

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Behavioral Health & Neurocognitive Therapeutics (Digital) (HLACANAI)

akta.pro secondary industries

Smoking Cessation & Nicotine Replacement Therapy (NRT) (HLAIADAH), Substance Use Prevention & Recovery Lifestyle Education (Non-clinical) (EDAAAHAL)

Keywords

• Digital therapeutics
• Smoking cessation app
• Cognitive behavioral therapy
• Medical device software
• Addiction care platform

Headquarters

HQ city

Paris

HQ country

France

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B and B2C

Offering type

Software

Cost components

Personnel, Technology or R&D, Marketing or Sales, Operations, Infrastructure

Revenue model

1. Digital Therapeutic Sales: Quitoxil app sold as a medical device, with reimbursement available through health insurance providers (mutuelles) ranging from €50 to €300 per year, and planned reimbursement as a digital medical device via PECAN program in 2025.
2. Healthcare Professional Prescription: Healthcare professionals prescribe Quitoxil via AppThera platform; patients receive email/SMS with download link and unique activation code.
3. Enterprise/B2B Licensing: Business development targeting insurance companies and enterprise clients for licenses and corporate wellness tool deployment.

Pricing tiers

Go-to-market motion3 records

Distribution channels4 records

Marketing channels5 records

Core offering

Klava Innovation develops and sells Quitoxil®, a CE-marked Class I digital medical device that delivers cognitive-behavioral therapy (CBT) via a smartphone application for smoking cessation. The product combines self-assessments, progress tracking, peer support from certified former smokers, and machine-learning-driven relapse risk detection, and is distributed through pharmacies, app stores, and healthcare professional prescription via the AppThera platform.

Product overview

KLAVA Innovation offers a single core product portfolio centered on Quitoxil®, a digital therapeutic medical device for addiction treatment. Quitoxil® is a comprehensive smartphone-based platform that delivers cognitive-behavioral therapy (CBT) for smoking cessation, featuring self-assessment tracking, peer support from certified patient experts, and a library of educational content. The product is prescribed through the AppThera platform and is distributed via pharmacies. KLAVA positions itself as the first French pharmaceutical laboratory specializing in digital treatment of addictions (tobacco, alcohol, opioids, sugar), with Quitoxil® as its flagship offering.

Differentiator

Problem solved

Functional benefit

Brands

• Quitoxil®: First French digital therapeutic medical device (Class I) indicated for smoking cessation, based on cognitive-behavioral therapy principles.

Products and services

• Quitoxil® CE-marked Class I digital medical device delivered as a smartphone application providing 24/7 personalized cognitive-behavioral therapy for smoking cessation. Features include self-assessments, craving and consumption tracking, peer support from certified former smokers, machine-learning relapse risk detection, and integration with the AppThera prescription platform for healthcare professionals.

Quantifiable outcome

• 51% of patients reduced their tobacco consumption
• +2 more outcomes

Named customers4 records

Segments4 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration1 record

AI capability5 records

Feature4 records

Partnerships

Eight partnerships are on record, tiered core and minor.

• France Patients Experts Addictions (FPEA)coreStrategic or Co-development Partner · 1 September 2023Partnership for peer support program within Quitoxil app. Certified former smokers (patients experts) provide empathetic support to app users, available 9am-7pm without appointment. Four-step coaching: listening, reassuring, advising, and encouraging.
• AP-HP Paul Brousse HospitalcoreStrategic or Co-development PartnerClinical partnership with the Addiction Department at AP-HP Paul Brousse Hospital, the leading addiction research department in Europe. Collaborates on feasibility study and proof of concept; conducts clinical studies with nearly 100 patients daily. KLAVA aims to improve patient access to equitable care in addiction treatment.
• AppTheracoreTechnology or IntegrationPrescription software platform enabling healthcare professionals to prescribe Quitoxil digitally. Free, secure platform accessible via CPS or e-CPS card. Prescription generates unique activation code for patients sent via email and SMS.
• ISIS MedicalminorOthersListed as partner on company website
• French Care (La French Care)minorOthersListed as partner on company website; healthcare ecosystem network
• France BiotechminorOthersListed as partner on company website; health innovation association
• Nexus ProminorOthersListed as partner on company website; pharmacy solutions provider
• Nice Côte d'AzurminorOthersListed as partner on company website; regional development agency

Scale indicators7 records

Recent moves8 records

Expansion highlights7 records

Direct peers

• Pelago (formerly Quit Genius): Pelago is a digital health company specializing in tobacco, alcohol, and opioid cessation programs delivered through employers, health plans, and providers. Like Klava, it offers a CBT-backed digital therapeutic for smoking cessation, making it the most direct global comparable for Quitoxil.
• Click Therapeutics: Click Therapeutics is a US-based prescription digital therapeutics company developing FDA-cleared software as a medical device, including a smoking cessation program (Clickotine). Comparable to Klava as a DTx player targeting regulated reimbursement pathways for behavioral addictions.
• CureApp: CureApp is a Japanese digital therapeutics company whose flagship product treats nicotine dependence and is reimbursed under Japan's national health system. It is the closest international analog for Klava's regulated, reimbursed DTx model for smoking cessation.
• Voluntis (AstraZeneca): Voluntis was a French prescription digital therapeutic company (now part of AstraZeneca) focused on chronic disease digital therapies including oncology and diabetes. Comparable to Klava as a French-headquartered DTx developer of medical-device software for reimbursed use.

Broad incumbents

• Akili Interactive: Akili Interactive is a publicly-traded digital therapeutics company with FDA-cleared prescription video game-based therapy for ADHD. It is comparable to Klava as a regulated DTx platform pursuing behavioral and cognitive health indications.
• Omada Health: Omada Health is a US digital chronic disease company offering behavior change programs for diabetes, hypertension, and musculoskeletal conditions, reimbursed by employers and payers. Comparable to Klava as a digital behavior-change therapeutic sold through payer channels.
• Hinge Health: Hinge Health is a large digital musculoskeletal and chronic pain platform providing exercise therapy and education reimbursed by US employers. It is comparable to Klava as a scaled category-defining digital therapeutic reimbursed by enterprise payers.
• Johnson & Johnson (Nicorette/Nicotinell): Johnson & Johnson's consumer health division markets Nicorette and Nicotinell, the leading OTC nicotine replacement therapy brands in France and Europe. Comparable to Klava as a competing smoking-cessation intervention sold in pharmacies, though via pharmacological rather than digital mechanism.

Emerging players

• Happify Health: Happify Health develops digital mental health and behavioral solutions, including evidence-based apps for stress, anxiety, and chronic conditions. Comparable to Klava as a digital behavior-change therapy company intersecting the mental health and addiction spaces.
• Big Health (Sleepio): Big Health develops Sleepio and Daylight, prescription-grade digital therapeutics for insomnia and anxiety sold through employers and health plans. Comparable to Klava as a regulated, evidence-based behavioral DTx reimbursed through payer and enterprise channels.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/klava-innovation

Compliance3 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Klava Innovation